OBJECTIVE: No substantial improvement in overall survival has been obtained over the past two decades in penile cancer (PC). Clinical data are available on the role of epidermal growth factor receptors (EGFR) inhibitors in PC but no EGFR mutational analysis has been conducted. RESEARCH DESIGN AND METHODS: We reviewed formalin-fixed, paraffin-embedded blocks of PC at the Pathology Department of the National Cancer Institute since 2000 through 2012 to evaluate activating mutations in the tyrosine kinase domain of EGFR: EGFR E746 - A750 specific deletion in exon 19 and EGFR L858R specific point mutation in exon 21. RESULTS: Thirty tumor samples were available for our analysis. EGFR was expressed in all samples at immunohistochemistry. Tested mutations were not identified in any of the samples analyzed. CONCLUSIONS: The most frequent activating EGFR mutations detected in non-small setting lung cancer are absent in penile cancer (PC). Sequencing of the entire EGFR gene in patients with PC may provide useful insights, as its mechanism of overexpression and activation in PC remains unknown.
OBJECTIVE: No substantial improvement in overall survival has been obtained over the past two decades in penile cancer (PC). Clinical data are available on the role of epidermal growth factor receptors (EGFR) inhibitors in PC but no EGFR mutational analysis has been conducted. RESEARCH DESIGN AND METHODS: We reviewed formalin-fixed, paraffin-embedded blocks of PC at the Pathology Department of the National Cancer Institute since 2000 through 2012 to evaluate activating mutations in the tyrosine kinase domain of EGFR: EGFR E746 - A750 specific deletion in exon 19 and EGFRL858R specific point mutation in exon 21. RESULTS: Thirty tumor samples were available for our analysis. EGFR was expressed in all samples at immunohistochemistry. Tested mutations were not identified in any of the samples analyzed. CONCLUSIONS: The most frequent activating EGFR mutations detected in non-small setting lung cancer are absent in penile cancer (PC). Sequencing of the entire EGFR gene in patients with PC may provide useful insights, as its mechanism of overexpression and activation in PC remains unknown.
Authors: Carlo Buonerba; Giuseppe Di Lorenzo; Gregory Pond; Giacomo Cartenì; Sarah Scagliarini; Antonio Rozzi; Fernando J Quevedo; Tanya Dorff; Lucia Nappi; Gaetano Lanzetta; Lance Pagliaro; Bernhard J Eigl; Gurudatta Naik; Matteo Ferro; Mariano Galdiero; Sabino De Placido; Guru Sonpavde Journal: Front Pharmacol Date: 2016-12-20 Impact factor: 5.810
Authors: Carlo Buonerba; Luca Scafuri; Ferdinando Costabile; Bruno D'Ambrosio; Simona Gatani; Pasquale Verolino; Rossella Di Trolio; Vincenzo Cosimato; Antonio Verde; Giuseppe Di Lorenzo Journal: Future Sci OA Date: 2021-05-21
Authors: Giuseppe Di Lorenzo; Sisto Perdonà; Carlo Buonerba; Guru Sonpavde; Vincenzo Gigantino; Giuseppe Pannone; Giuseppe Quarto; Matteo Ferro; Gabriella Gaudioso; Daniela Terracciano; Rossella Di Trolio; Pasquale Rescigno; Gerardo Botti; Sabino De Placido; Gaetano Facchini; Paolo A Ascierto; Renato Franco Journal: J Transl Med Date: 2013-07-02 Impact factor: 5.531